Ovdje možete pogledati online predavanje vodećeg genetičara Josefa Penningera pod nazivom “ACE2 – a rational frontline therapy for COVID-19″, koje će se održati 12. ožujka 2020. u 17 sati, a od velikog je interesa za medicinske profesionalce.
In spite of the challenging times, the ESR remains committed to public health and the fight against the novel coronavirus disease.
It is therefore our great pleasure to invite you to join us for the upcoming ESR Connect LIVE event, a lecture by one of the world’s leading geneticists and molecular immunologists, Prof. Josef Penninger.
Born in Austria, Penninger is the current Director of the Life Sciences Institute at the University of British Columbia in Vancouver, Canada, and guest professor of genetics at the Medical University Vienna. APEIRON Biologics AG, a company he founded, recently started a pilot clinical trial for their newly developed drug that is supposed to decrease mortality in COVID-19 patients.
His lecture will shed light on the discovery and function of ACE2 (angiotensin converting enzyme 2) and its predisposition as a SARS-CoV and SARS-CoV-2 receptor. (see his latest publication: Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med (2020). https://doi.org/10.1007/s00134-020-05985-9)
The lecture will be free-of-charge and accessible to all.
We kindly ask for your help by sharing the following information with your co-workers and friends, as this lecture will certainly be of interest for all physicians and scientists, beyond radiology:
ACE2 – a rational frontline therapy for COVID-19
Online lecture by world-leading geneticist Josef Penninger
Free of charge – March 12, 17:00 CET